Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-07-21 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物药业（南京）股份有限公司2022年度以简易程序向特定对象发行A股股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed plan and proposal for a 2022 private placement (non-public issuance) of A shares by Frontier Biotechnologies Inc. It includes extensive information about the company, the background and purpose of the issuance, the pricing, the investors involved, the use of proceeds, regulatory compliance, and risk disclosures. The document references regulatory frameworks such as the Shanghai Stock Exchange and China Securities Regulatory Commission rules, and it is clearly a comprehensive issuance plan rather than a simple announcement. It contains substantive financial and operational details related to the capital raising and its impact on the company. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an Annual Report, Earnings Release, or Proxy Statement, nor is it a simple announcement of a report publication. It is a detailed financing plan document with over 15,000 characters, indicating it is the full plan rather than a brief notice.
2022-07-21 Chinese
前沿生物独立董事关于第三届董事会第二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various proposals related to the company's issuance of shares via a simplified procedure to specific targets in 2022. It references compliance with securities laws, issuance registration management measures, and includes opinions on the legality, fairness, and accuracy of the issuance process and related documents. The document is not a full financial report but rather an official opinion on board meeting matters related to capital raising and share issuance. The document length is 2666 characters, which is relatively short and focused on board meeting agenda items and independent opinions. This fits best with Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on company actions, especially regarding share issuance and related approvals. It is not an announcement of a report, nor a full financial report, nor a regulatory filing or proxy solicitation. Therefore, the classification is MANG with high confidence.
2022-07-21 Chinese
前沿生物关于第三届董事会第二次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of a company. It details the approval of various proposals related to a specific capital raising event, including the issuance of shares to specific investors, signing of subscription agreements, and updates to related documents. The document includes voting results and references to regulatory compliance but does not contain financial statements or detailed financial analysis itself. It is a formal announcement of board decisions rather than a full financial report or a detailed presentation. Therefore, it fits best into the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2022-07-21 Chinese
毕马威华振会计师事务所（特殊普通合伙）关于前沿生物药业（南京）股份有限公司非经常性损益明细表的鉴证报告
Regulatory Filings
2022-07-21 Chinese
前沿生物药业（南京）股份有限公司2022年度以简易程序向特定对象发行A股股票方案论证分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022年度以简易程序向特定对象发行A股股票方案论证分析报告 (Revised)" which translates to "2022 Annual Report on the Proposal and Analysis of a Simplified Procedure for Private Placement of A Shares." The content extensively discusses the background, purpose, and details of a private placement (non-public issuance) of shares to specific investors, including the number of shares, pricing, and regulatory compliance. It also elaborates on the company's strategic rationale for the issuance, the use of proceeds, and the selection of investors. This is a detailed report related to a capital raising activity through issuance of new shares to specific investors, which fits the definition of a Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains substantive analysis and data supporting the financing plan, not merely an announcement or a brief notice. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). It is not an Annual Report (10-K), Earnings Release (ER), or other categories. Hence, the appropriate classification is CAP with high confidence.
2022-07-21 Chinese
前沿生物关于2022年度以简易程序向特定对象发行股票摊薄即期回报的风险提示及填补措施和相关主体承诺（修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding a specific stock issuance using a simplified procedure to certain investors. It discusses the impact of this issuance on the company's financial metrics, risk warnings about dilution of immediate returns, the necessity and rationale for the issuance, the company's measures to mitigate dilution risks, and commitments from the board and controlling shareholders to uphold these measures. The document includes financial assumptions, projections, and detailed explanations about the use of proceeds and governance commitments. It is not a full annual or quarterly report, nor is it a simple announcement of a report publication. It is a capital/financing update related to a specific equity issuance and its financial impact and risk disclosures. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-07-21 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.